CN1243444A - 被修饰的肿瘤坏死因子 - Google Patents
被修饰的肿瘤坏死因子 Download PDFInfo
- Publication number
- CN1243444A CN1243444A CN98801837A CN98801837A CN1243444A CN 1243444 A CN1243444 A CN 1243444A CN 98801837 A CN98801837 A CN 98801837A CN 98801837 A CN98801837 A CN 98801837A CN 1243444 A CN1243444 A CN 1243444A
- Authority
- CN
- China
- Prior art keywords
- tnf
- peg
- adorned
- tumor
- covalent bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
处理组 | 结果 |
对照 | 4只死,1只有大肿瘤 |
天然TNF-α | |
10I.U. | 动物都死 |
100I.U. | 4只死,1只有大肿瘤 |
5000MW SS-PEG-TNF-α | |
10I.U. | 2只死,3只有大肿瘤 |
100I.U. | 2只死,2只有肿瘤,1只没肿瘤 |
1000I.U. | 1只死,3只有小肿瘤,1只没有肿瘤 |
20000MW SS-PEG-TNF-α | |
10I.U. | 0只死,1只有小肿瘤,4只无肿瘤 |
100I.U. | 都没有肿瘤 |
1000I.U. | 都没有肿瘤 |
处理组 | 存活时间 | 平均 |
对照组 | 18、18、20、21、24天 | 20.2天 |
天然TNF-α | ||
10I.U. | 17、18、19、21、21天 | 20.2天 |
100I.U. | 16、18、19、19、23天 | 19.0天 |
5000MW SS-PEG-TNF-α | ||
10I.U. | 20、22、24、26、27天 | 23.6天 |
100I.U. | 21、22、24、26、27天 | 35.0天 |
1000I.U. | 21、49、53天;2只仍存活 | |
20000MW SS-PEG-TNF-α | ||
10I.U. | 38天,4只仍存活 | |
100I.U. | 5只都存活 | |
1000I.U. | 5只都存活 |
处理 | 血清半衰期(天) | %保留的比活性 |
SS-PEG5000TNF-α(2次试验) | 4,4 | 55,58 |
SS-PEG12000TNF-α(2次试验) | 8,8 | 52,53 |
SS-PEG20000TNF-α | 16 | 56 |
SS-PEG30000TNF-α | 17 | 54 |
SS-PEG40000TNF-α | 17 | 55 |
SS-PEG5000TNF-α | 5 | 51 |
SS-PEG20000TNF-α | 8 | 53 |
支链琥珀酰亚胺-PEG10000TNF-α | 7 | 49 |
支链琥珀酰亚胺-PEG20000TNF-α | 16 | 52 |
支链琥珀酰亚胺-PEG40000TNF-α | 18 | 54 |
处理(#PEG/TNF ) | 血清半衰期(天) | %保留的比活性 |
SCM-PEG5000TNF-α(5-9个PEG) | 5 | 54 |
氨基酸的琥珀酰亚胺酯-PEG5000TNF-α(6-8个PEG) | 4 | 55 |
环氧PEG8000TNF-α(伯胺结合点)(10-20个PEG) | 6 | 38 |
环氧PEG8000TNF-α(羟基结合点)(10-20个PEG) | 5 | 0 |
缩水甘油醚PEG5000TNF-α(15个PEG) | 12 | 0 |
硝基苯基PEG5000TNF-α(6-9个PEG) | 5 | 21 |
碳酸三氯苯酯PEG5000TNF-α(12-15个PEG) | 5 | 11 |
PEG Tresylate5000TNF-α(10-12个PEG) | 2 | 8 |
PEG醛5000TNF-α(1个PEG) | <1 | 100 |
PEG醛20000TNF-α(1个PEG) | 2 | 100 |
PEG异氰酸酯5000TNF-α(5-12个PEG) | 9 | 19 |
PEG乙烯砜5000TNF-α(4个PEG) | 3 | 12 |
PEG顺丁烯二酰亚胺5000TNF-α(3个PEG) | 3 | 43 |
肿瘤类型 | 细胞系 | PEG-TNF的剂量I.U. | %治愈率 |
黑色素瘤 | B16 | 10 | 75 |
30 | 100 | ||
100 | 100 | ||
肾瘤 | G401 | 10 | 80 |
30 | 80 | ||
结肠瘤 | HT29 | 10 | 40 |
30 | 60 | ||
100 | 80 | ||
乳腺癌 | MCF7 | 10 | 0 |
30 | 0 | ||
100 | 20 | ||
脑瘤 | SW1088 | 100 | 0 |
白血病 | L1210 | 100 | 0 |
肝细胞癌 | Hep3B | 100 | 0 |
TNF蛋白质 | 比活性 | LD50 | 低血压ED50 | 抗肿瘤ED50 |
在Pichea中产生的重组鼠TNF | 2.1×107IU/mg | 20μg | 1μg | >1000IU |
用SS-PEGMW20000修饰的在Pichea中产生的重组鼠TNF | 1.0×107IU/mg | 100μg | 2μg | 20IU |
在大肠杆菌中产生的重组鼠TNF | 2.0×107IU/mg | 70μg | 1μg | >3000IU |
用SS-PEGMW20000修饰的在大肠杆菌中产生的重组鼠TNF | 1.0×107IU/mg | 300μg | 4μg | 20IU |
通过缺失212-222位的氨基酸突变得到的人TNF | 2.1×107IU/mg | 60μg | 1μg | >2000IU |
用SS-PEGMW20000修饰的通过缺失212-222位的氨基酸突变得到的人TNF | 0.9×107IU/mg | 100μg | 5μg | 10IU |
通过把248、592、508赖氨酸转变为丙氨酸突变得到的人TNF | 1.5×107IU/mg | 300μg | 100μg | >1000IU |
用SS-PEG MW20000修饰的通过把248、592、508赖氨酸转变为丙氨酸突变得到的人TNF | 0.5×107IU/mg | >1000μg | >100μg | 5IU |
Claims (17)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3552197P | 1997-01-15 | 1997-01-15 | |
US60/035,521 | 1997-01-15 | ||
US681098A | 1998-01-14 | 1998-01-14 | |
US09/006,810 | 1998-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1243444A true CN1243444A (zh) | 2000-02-02 |
CN1168495C CN1168495C (zh) | 2004-09-29 |
Family
ID=26676095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988018373A Expired - Lifetime CN1168495C (zh) | 1997-01-15 | 1998-01-15 | 被修饰的肿瘤坏死因子 |
Country Status (11)
Country | Link |
---|---|
US (1) | US7785579B2 (zh) |
EP (1) | EP1007082B1 (zh) |
JP (1) | JP4295831B2 (zh) |
CN (1) | CN1168495C (zh) |
AT (1) | ATE342729T1 (zh) |
AU (1) | AU725133B2 (zh) |
CA (1) | CA2277757C (zh) |
DE (1) | DE69836222T2 (zh) |
DK (1) | DK1007082T3 (zh) |
ES (1) | ES2275300T3 (zh) |
WO (1) | WO1998031383A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001075029A2 (fr) * | 2000-03-24 | 2001-10-11 | Shanghai Biowindow Gene Development Inc. | Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide |
CN100339393C (zh) * | 2001-02-23 | 2007-09-26 | 霍夫曼-拉罗奇有限公司 | Hgf-nk4的peg-偶联物 |
CN101837130B (zh) * | 2009-03-20 | 2013-10-23 | 北京大学 | 聚乙二醇-二肽-抗肿瘤药物复合物及其用途 |
CN105121640A (zh) * | 2013-03-14 | 2015-12-02 | Ran生物技术公司 | 用于微生物捕集的方法和材料 |
CN105294852A (zh) * | 2015-10-27 | 2016-02-03 | 岳阳新华达制药有限公司 | 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途 |
US11578351B2 (en) | 2013-03-14 | 2023-02-14 | Ran Biotechnologies, Inc. | Methods and materials for detection of biologicals |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
CN102161984B (zh) | 1998-08-06 | 2016-06-01 | 山景药品公司 | 分离四聚体尿酸氧化酶的方法 |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
JP2004528025A (ja) | 2001-02-21 | 2004-09-16 | サーロメッド・インコーポレーテッド | 修飾されたアネキシン蛋白質及び血栓症を防ぐための方法 |
US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
US7655618B2 (en) | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
AU2003303634B2 (en) | 2002-12-27 | 2009-10-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드-종결 중합체 |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
WO2005056636A2 (en) | 2003-12-03 | 2005-06-23 | Nektar Therapeutics Al, Corporation | Method of preparing maleimide functionalized polymers |
JP4877225B2 (ja) | 2005-02-18 | 2012-02-15 | 日油株式会社 | ポリオキシアルキレン誘導体 |
WO2006110761A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | A variant form of urate oxidase and use thereof |
HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
PL2013225T3 (pl) | 2006-04-12 | 2015-06-30 | Crealta Pharmaceuticals Llc | Oczyszczanie białek z zastosowaniem kationowego środka powierzchniowo czynnego |
KR100886783B1 (ko) * | 2006-06-12 | 2009-03-04 | 성균관대학교산학협력단 | N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도 |
US20100284962A1 (en) * | 2009-05-06 | 2010-11-11 | Oncopharmacologics, Inc. | Modified tumor necrosis factor-beta |
MX347903B (es) | 2009-06-25 | 2017-05-18 | Crealta Pharmaceuticals Llc | Metodos y equipos para predecir el riesgo de reaccion a la infusion y perdida de respuesta mediada por anticuerpos al supervisar el acido urico en suero durante una terapia con uricasa conjugada con peg. |
EA038551B1 (ru) | 2015-12-17 | 2021-09-14 | Дзе Джонс Хопкинс Юниверсити | Способ лечения или профилактики системного склероза |
EA201892260A1 (ru) | 2016-04-07 | 2019-03-29 | Дзе Джонс Хопкинс Юниверсити | Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
US5447722A (en) | 1983-12-12 | 1995-09-05 | University Of Manitoba | Method for the suppression of an immune response with antigen-MPEG conjugates in nonsensitized individuals |
DE3676670D1 (de) * | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
JPH04502011A (ja) | 1988-11-23 | 1992-04-09 | ジェネンテク,インコーポレイテッド | ポリペプチド誘導体 |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
WO1994005332A2 (en) | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
KR970005042B1 (ko) | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US5747639A (en) * | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
-
1998
- 1998-01-15 DK DK98904563T patent/DK1007082T3/da active
- 1998-01-15 WO PCT/US1998/000683 patent/WO1998031383A1/en active IP Right Grant
- 1998-01-15 AU AU62410/98A patent/AU725133B2/en not_active Expired
- 1998-01-15 ES ES98904563T patent/ES2275300T3/es not_active Expired - Lifetime
- 1998-01-15 EP EP98904563A patent/EP1007082B1/en not_active Expired - Lifetime
- 1998-01-15 DE DE69836222T patent/DE69836222T2/de not_active Expired - Lifetime
- 1998-01-15 CA CA002277757A patent/CA2277757C/en not_active Expired - Lifetime
- 1998-01-15 CN CNB988018373A patent/CN1168495C/zh not_active Expired - Lifetime
- 1998-01-15 JP JP53448898A patent/JP4295831B2/ja not_active Expired - Lifetime
- 1998-01-15 AT AT98904563T patent/ATE342729T1/de active
-
2006
- 2006-02-27 US US11/363,863 patent/US7785579B2/en not_active Expired - Fee Related
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001075029A2 (fr) * | 2000-03-24 | 2001-10-11 | Shanghai Biowindow Gene Development Inc. | Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide |
WO2001075029A3 (fr) * | 2000-03-24 | 2002-05-10 | Shanghai Biowindow Gene Dev | Nouveau polypeptide, facteur humain 11 associe a nf-e2, et polynucleotide codant pour ce polypeptide |
CN100339393C (zh) * | 2001-02-23 | 2007-09-26 | 霍夫曼-拉罗奇有限公司 | Hgf-nk4的peg-偶联物 |
CN101837130B (zh) * | 2009-03-20 | 2013-10-23 | 北京大学 | 聚乙二醇-二肽-抗肿瘤药物复合物及其用途 |
CN105121640A (zh) * | 2013-03-14 | 2015-12-02 | Ran生物技术公司 | 用于微生物捕集的方法和材料 |
US10105681B2 (en) | 2013-03-14 | 2018-10-23 | Ran Biotechnologies, Inc. | Methods and materials for microorganism capture |
US11123708B2 (en) | 2013-03-14 | 2021-09-21 | Ran Biotechnologies, Inc. | Methods and materials for microorganism capture |
US11578351B2 (en) | 2013-03-14 | 2023-02-14 | Ran Biotechnologies, Inc. | Methods and materials for detection of biologicals |
CN105294852A (zh) * | 2015-10-27 | 2016-02-03 | 岳阳新华达制药有限公司 | 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途 |
CN105294852B (zh) * | 2015-10-27 | 2019-06-07 | 岳阳新华达制药有限公司 | 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途 |
Also Published As
Publication number | Publication date |
---|---|
DE69836222T2 (de) | 2007-11-15 |
AU725133B2 (en) | 2000-10-05 |
EP1007082B1 (en) | 2006-10-18 |
US7785579B2 (en) | 2010-08-31 |
CA2277757A1 (en) | 1998-07-23 |
ATE342729T1 (de) | 2006-11-15 |
AU6241098A (en) | 1998-08-07 |
CN1168495C (zh) | 2004-09-29 |
ES2275300T3 (es) | 2007-06-01 |
US20060222626A1 (en) | 2006-10-05 |
CA2277757C (en) | 2008-09-16 |
DE69836222D1 (de) | 2006-11-30 |
EP1007082A4 (en) | 2004-05-12 |
JP4295831B2 (ja) | 2009-07-15 |
EP1007082A1 (en) | 2000-06-14 |
DK1007082T3 (da) | 2007-02-19 |
JP2001511784A (ja) | 2001-08-14 |
WO1998031383A1 (en) | 1998-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1168495C (zh) | 被修饰的肿瘤坏死因子 | |
CN1960766A (zh) | 新的g-csf轭合物 | |
CN1187094C (zh) | 多元醇干扰素β偶联物 | |
CN100366742C (zh) | Il-2选择性激动剂和拮抗剂 | |
DE69836438T2 (de) | Substantiell reine histidin-gebundene protein polymerkonjugate | |
CN1173183A (zh) | 含有水溶性聚合物的bdnf与nt-3的结合物 | |
CN1145636A (zh) | 血管内皮生长因子2 | |
WO1998031383A9 (en) | Modified tumor necrosis factor | |
CN1047035A (zh) | 生物应答修饰因子的新颖抗体传递系统 | |
CN1341122A (zh) | 共价桥接的胰岛素二聚物 | |
CN106928339A (zh) | 经修饰的牛g‑csf多肽和其用途 | |
US4462985A (en) | Delivery of biologically active components of heterologous species interferon isolates | |
CN1322246A (zh) | 静息蛋白及其使用方法 | |
CN101213208A (zh) | 粒细胞集落形成刺激因子(g-csf)的突变体及其化学缀合多肽 | |
WO1982000588A1 (en) | Delivery of biologically active components of heterologous species interferon isolates | |
CN1735428A (zh) | 伴侣蛋白10的免疫抑制作用 | |
CN1053838C (zh) | 肿瘤坏死因子和白细胞介素-4的协同 | |
CN1065875C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN1191271C (zh) | 干扰素-胸腺肽融合蛋白及其制法 | |
CN1569892A (zh) | 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法 | |
CN1232532C (zh) | 成纤维细胞生长因子-2结构类似物,其生产方法及应用 | |
CN100335499C (zh) | C端氨基酸内酯修饰型胸腺素α1及其应用 | |
CN1769299A (zh) | 一种新型融合蛋白的制造及应用 | |
CN1240436C (zh) | 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用 | |
CN1197873C (zh) | 人结缔组织生长因子及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RIPE GROUP CO., LTD. Free format text: FORMER OWNER: PHOENIX PHARMACOLOGICS INC. Effective date: 20080912 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: California, USA Patentee after: Puri Group Co. Address before: American Pennsylvania Patentee before: PHOENIX PHARMACOLOGICS, Inc. |
|
CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Phonenix Pharmacologics, Inc. False: Puri Group Co Number: 42 Page: 1461 Volume: 24 |
|
ERR | Gazette correction |
Free format text: CORRECT: PATENTEE; FROM: RIPE GROUP CO., LTD. TO: PHOENIX PHARMACOLOGICS INC. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: California, USA Patentee after: PHOENIX PHARMACOLOGICS, Inc. Address before: American Pennsylvania Patentee before: PHOENIX PHARMACOLOGICS, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20081205 Address after: Taiwan, China Tai Bei Patentee after: Puri Group Co. Address before: California, USA Patentee before: PHOENIX PHARMACOLOGICS, Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: RIPE GROUP CO., LTD. Free format text: FORMER OWNER: PHOENIX PHARMACOLOGICS INC. Effective date: 20081205 |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20040929 |